Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Letrozole maintenance in NSMP endometrial cancer
NCT05454358Phase 3Terminated
- Sponsor
- Fudan University
- Start
- Aug 2022
- Primary completion
- Dec 2025
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of letrozole in endometrial cancer (EC), sponsored by Fudan University. Primary endpoint: Progression-Free Survival at 3 years. Started Aug 2022; status: terminated.
02
Drugs
letrozole
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NCT05454358.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05454358.